2,784 results match your criteria: "Aichi Cancer Center Hospital.[Affiliation]"
Efficacy of chemotherapy for patients with gastric cancer with early recurrence during or after adjuvant chemotherapy with S-1 alone: a multicenter retrospective study.
Sci Rep
September 2024
Department of Oncology and General Medicine, IMSUT Hospital, Institute of Medical Science, University of Tokyo, Tokyo, Japan.
Article Synopsis
- * Most patients received paclitaxel-based treatments (49%), followed by fluoropyrimidines plus platinum (44%), and irinotecan (7%), with overall response rates of 28.7% and disease control rates of 54.1%.
- * Results indicated a median progression-free survival (PFS) of 5.1 months and overall survival (OS) of 12.9 months, with the combination of paclitaxel and ramucirumab
A novel traction method using a multi-loop traction device in colorectal endoscopic submucosal dissection: Anchor traction method.
Endoscopy
December 2024
Department of Endoscopy, Aichi Cancer Center Hospital, Nagoya, Japan.
Survival benefit of adjuvant chemotherapy based on molecular residual disease detection in resected colorectal liver metastases: subgroup analysis from CIRCULATE-Japan GALAXY.
Ann Oncol
November 2024
Department of Surgery and Science, Graduate School of Medical Sciences, Kyushu University, Fukuoka. Electronic address:
Article Synopsis
- * Among 190 patients evaluated, 32.1% tested positive for ctDNA post-surgery; adjuvant chemotherapy (ACT) significantly improved disease-free survival (DFS) for MRD-positive patients, while it showed no advantage for MRD-negative patients.
- * Key findings indicate that the size of liver metastases correlates with DFS in MRD-positive patients, emphasizing the importance of MRD status in guiding treatment decisions post-surgery.
Novel MLH1 nonsense variant in a patient with suspected Lynch syndrome.
Hum Genome Var
September 2024
Risk Assessment Unit, Aichi Cancer Center Hospital, Nagoya, Japan.
Article Synopsis
- Loss-of-function germline variants in the MLH1 gene are linked to Lynch syndrome, a hereditary condition that increases cancer risk.
- A 43-year-old male patient was diagnosed with cecal and transverse colon adenocarcinomas, which fit the revised Bethesda guidelines for Lynch syndrome assessment.
- Genetic testing revealed a novel pathogenic variant in the MLH1 gene, confirming the diagnosis of Lynch syndrome for this patient.
ctDNA-based molecular residual disease and survival in resectable colorectal cancer.
Nat Med
November 2024
Department of Surgery and Science, Graduate School of Medical Sciences, Kyushu University, Fukuoka, Japan.
The interim analysis of the CIRCULATE-Japan GALAXY observational study demonstrated the association of circulating tumor DNA (ctDNA)-based molecular residual disease (MRD) detection with recurrence risk and benefit from adjuvant chemotherapy (ACT) in resectable colorectal cancer (CRC). This updated analysis with a 23-month median follow-up, including 2,240 patients with stage II-III colon cancer or stage IV CRC, reinforces the prognostic value of ctDNA positivity during the MRD window with significantly inferior disease-free survival (DFS; hazard ratio (HR): 11.99, P < 0.
View Article and Find Full Text PDFOptimal choice of first-line treatment for advanced renal cell carcinoma based on the results of extended follow-up data.
Transl Androl Urol
August 2024
Department of Urology, Aichi Cancer Center Hospital, Nagoya, Japan.
Durvalumab after chemoradiotherapy for locoregional recurrence of completely resected non-small-cell lung cancer (NEJ056).
Cancer Sci
November 2024
Department of Respiratory Medicine, Faculty of Medicine, Hokkaido University, Sapporo, Japan.
Article Synopsis
- The study investigates the effectiveness of durvalumab combined with chemoradiotherapy (CRT) versus CRT alone in treating locoregional recurrence of non-small-cell lung cancer (NSCLC) after complete resection.
- Using propensity score analysis to adjust for confounding variables, the research involved 119 patients in the CRT-D group and 111 in the CRT group, noting differences in gender distribution and adenocarcinoma rates.
- Results indicated that the median progression-free survival was significantly longer in the CRT-D group (25.4 months) compared to the CRT group (11.5 months), suggesting that the combination treatment could be a beneficial strategy for these patients.
Results from the randomized KEYNOTE-355 study of pembrolizumab plus chemotherapy for Asian patients with advanced TNBC.
NPJ Breast Cancer
September 2024
Centre for Experimental Cancer Medicine, Barts Cancer Institute, London, UK.
Article Synopsis
- The phase 3 KEYNOTE-355 study showed that pembrolizumab combined with chemotherapy significantly improved progression-free survival (PFS) and overall survival (OS) in patients with untreated, advanced triple-negative breast cancer and high PD-L1 levels compared to placebo with chemotherapy.
- Approximately 64% of patients enrolled in Asian countries, such as Hong Kong, Japan, and Malaysia, had tumors with a PD-L1 combined positive score of 1 or higher, with 35% having a score of 10 or higher.
- Treatment with pembrolizumab plus chemotherapy resulted in manageable side effects, with similar rates of grade 3/4 adverse events compared to the placebo group, indicating a favorable benefit-risk profile.
Safety of a short-term infusion of fosnetupitant in patients with gastrointestinal and breast cancer: a prospective study.
Oncologist
September 2024
Department of Clinical Oncology, Aichi Cancer Center Hospital, Nagoya, Aichi 484-8681, Japan.
Article Synopsis
- Fosnetupitant is an anti-nausea medication used for patients undergoing chemotherapy, showing non-inferiority to another treatment in prior studies.
- A phase II study evaluated the safety of a faster 15-minute infusion of fosnetupitant in cancer patients, focusing on allergic reaction incidents and other side effects.
- Results indicated that the 15-minute infusion was safe, with no allergic reactions or severe side effects reported, and a high complete response rate of 87%.
Skeleton-guided 3D convolutional neural network for tubular structure segmentation.
Int J Comput Assist Radiol Surg
September 2024
Graduate School of Informatics, Nagoya University, Furo-cho, Chikusa-ku, Nagoya, Aichi, Japan.
Purpose: Accurate segmentation of tubular structures is crucial for clinical diagnosis and treatment but is challenging due to their complex branching structures and volume imbalance. The purpose of this study is to propose a 3D deep learning network that incorporates skeleton information to enhance segmentation accuracy in these tubular structures.
Methods: Our approach employs a 3D convolutional network to extract 3D tubular structures from medical images such as CT volumetric images.
Development of an external system for monitoring the couch speed in radiotherapy using continuous bed movement.
J Appl Clin Med Phys
November 2024
Department of Radiation Oncology, Aichi Cancer Center Hospital, Nagoya, Aichi, Japan.
Purpose: Total body irradiation before bone marrow transplantation for hematological malignancies using Radixact, a high-precision radiotherapy machine, can potentially reduce side effects and the risk of secondary malignancies. However, stable control of couch speed is critical, and direct assessment methods outlined in quality assurance guidelines are lacking. This study aims to develop a real-time couch speed verification system for the Radixact.
View Article and Find Full Text PDFThe effect of epidermal growth factor receptor mutation on adjuvant chemotherapy with tegafur/uracil for patients with completely resected, non-lymph node metastatic non-small cell lung cancer (> 2 cm): a multicenter, retrospective, observational study as exploratory analysis of the CSPOR-LC03 study.
Jpn J Clin Oncol
November 2024
Division of Thoracic Surgery, Department of Thoracic Oncology, National Cancer Center Hospital East, Chiba, Japan.
Article Synopsis
- The study examines the potential competition between adjuvant osimertinib and the current standard treatment, oral tegafur/uracil (UFT), for early-stage lung adenocarcinoma in Japan, particularly focusing on the impact of EGFR mutations on patient outcomes.
- Researchers analyzed data from 1812 patients with stage I adenocarcinoma to compare 5-year disease-free survival (DFS) rates based on their EGFR mutation status and whether they received UFT treatment.
- Results show that while the DFS rates varied by treatment and mutation status, adjuvant UFT did not provide a significant survival advantage, particularly in patients with EGFR mutations, indicating the need for alternative therapies in this group.
Capivasertib and fulvestrant for patients with hormone receptor-positive advanced breast cancer: characterization, time course, and management of frequent adverse events from the phase III CAPItello-291 study.
ESMO Open
September 2024
Royal Marsden Hospital, Institute of Cancer Research, London, UK.
Article Synopsis
- - Capivasertib, a selective pan-AKT inhibitor, was shown to significantly improve progression-free survival when added to fulvestrant compared to fulvestrant alone in patients with advanced breast cancer (P < 0.001), specifically those who had previously experienced disease progression on aromatase inhibitors.
- - In a randomized trial with 708 patients, individuals received either capivasertib plus fulvestrant or a placebo plus fulvestrant, with safety analyses revealing common adverse events (AEs) like diarrhea, rash, and hyperglycemia associated with capivasertib treatment.
- - Among 705 patients analyzed, 72.4% experienced diarrhea, while 38% had a rash
Peritoneal lavage cytology in patients with curative resection for stage II and III colorectal cancer: A multi-institutional prospective study.
Ann Gastroenterol Surg
September 2024
Division of Molecular and Diagnostic Pathology Niigata University, Graduate School of Medical and Dental Sciences Niigata Japan.
Article Synopsis
- Study aimed to assess the impact of intraoperative lavage cytology on patient outcomes in colorectal cancer surgeries, specifically focusing on stages II-III.
- Out of 1378 patients, lavage revealed positive cytology in only 54 cases, with significant differences in 5-year relapse-free survival and overall survival rates between positive and negative cytology in stage II patients.
- The findings indicate that negative cytology correlates with better outcomes and highlights the effectiveness of lavage cytology in predicting peritoneal recurrence in these cancer patients.
Is multidisciplinary treatment effective for invasive intraductal papillary mucinous carcinoma?
Ann Gastroenterol Surg
September 2024
Second Department of Surgery Wakayama Medical University, School of Medicine Wakayama Japan.
Article Synopsis
- * Analyzing data from 1183 patients, it found that completing 6 months of postoperative adjuvant therapy significantly improved overall, disease-specific, and recurrence-free survival, especially for high-risk patients.
- * Additionally, neoadjuvant therapy showed benefits for those with borderline resectable IPMC, and any treatment for recurrence after surgery was linked to longer survival compared to no treatment.
Aim: The aim of this study was to clarify the significance of blood culture testing in the postoperative period of pancreatoduodectomy (PD), a highly invasive surgery.
Methods: Rates of blood culture sampling and positivity were investigated for febrile episodes (FEs) in patients who underwent PD (2016-2021). FEs were defined as body temperature of 38.
Successful ureteral stent placement with rendezvous technique for ureteral obstruction after urinary diversion: A case report.
Radiol Case Rep
November 2024
Department of Diagnostic and Interventional Radiology, Aichi Cancer Center Hospital, Aichi, Japan.
Article Synopsis
- - Ureteral obstruction after urinary diversion is a common issue, usually treated with the placement of a ureteral stent through a nephrostomy.
- - A 64-year-old man with a history of rectal cancer and urinary diversion experienced bilateral ureteral obstruction due to postoperative adhesion, leading to bilateral nephrostomy.
- - Attempting both antegrade and retrograde approaches, the rendezvous technique allowed successful placement of an internal-external drainage catheter, helping the patient avoid permanent nephrostomy and maintaining his quality of life.
Real-world treatment costs of first-line treatment for metastatic colorectal cancer: a survey of the JCOG colorectal cancer study group.
Jpn J Clin Oncol
October 2024
Department of Colorectal Surgery, National Cancer Center Hospital, Tokyo, Japan.
Background: Although treatment outcomes for metastatic colorectal cancer (mCRC) have dramatically improved over the past few decades, drug costs have also significantly increased. This study aimed to investigate which first-line treatment regimens for mCRC are actually used (frequency) in Japanese practice and at what cost.
Methods: We collected data on patients with mCRC who received first-line treatment at 37 institutions of the Japan Clinical Oncology Group Colorectal Cancer Study Group from July 2021 to June 2022, and calculated the cost of regimens.
Frequency of use and cost in Japan of first-line palliative chemotherapies for recurrent or metastatic squamous cell carcinoma of the head and neck.
Jpn J Clin Oncol
October 2024
Department of Otolaryngology-Head and Neck Surgery, Faculty of Medicine, Graduate School of Medicine, Hokkaido University, Sapporo, Japan.
Background: Over the last decade, novel anticancer drugs have improved the prognosis for recurrent or metastatic squamous cell carcinoma of the head and neck (RM-SCCHN). However, this has increased healthcare expenditures and placed a heavy burden on patients and society. This study investigated the frequency of use and costs of select palliative chemotherapy regimens in Japan.
View Article and Find Full Text PDFClinical utility of BRCA and ATM mutation status in circulating tumour DNA for treatment selection in advanced pancreatic cancer.
Br J Cancer
October 2024
Department of Hepatobiliary and Pancreatic Oncology, National Cancer Center Hospital, Tokyo, Japan.
Article Synopsis
- The study focuses on using circulating tumor DNA (ctDNA) analysis to identify homologous recombination deficiency (HRD) and BRCA1/2 and ATM mutations in patients with advanced pancreatic cancer (APC).
- Out of 702 APC patients analyzed, 4.8% had BRCA1/2 mutations and 4.4% had ATM mutations, with those having BRCA mutations showing significantly better response rates to platinum-based chemotherapy compared to those without.
- ctDNA profiling is suggested as a valuable, non-invasive method for assessing mutation status and selecting appropriate treatments in advanced pancreatic cancer, offering a practical approach to HRD screening.
Prospective multicenter surveillance study of branch-duct intraductal papillary mucinous neoplasm of the pancreas; risk of dual carcinogenesis.
Pancreatology
November 2024
Department of Surgery and Oncology, Graduate School of Medical Sciences, Kyushu University, Fukuoka, Japan; Department of Surgery, Shimonoseki City Hospital, Shimonoseki, Yamaguchi, Japan. Electronic address:
Background: The natural history of branch-duct intraductal papillary mucinous cystic neoplasms (BD-IPMNs) in the pancreas remains unclear. This study aimed to answer this clinical question by focusing on the development of concomitant pancreatic ductal adenocarcinomas (cPDAC).
Methods: The Japan Pancreas Society conducted a prospective multicenter surveillance study of BD-IPMN every six months for five years.
Safety and efficacy of trans-afferent loop endoscopic ultrasound-guided pancreaticojejunostomy for post pancreaticoduodenectomy anastomotic stricture using the forward-viewing echoendoscope: a retrospective study from Japan.
Clin Endosc
August 2024
Department of Gastroenterology, Aichi Cancer Center Hospital, Nagoya, Japan.
Article Synopsis
- EUS-guided pancreaticojejunostomy (EUS-PJS) is an effective procedure for treating strictures after Whipple surgery, showing a 100% technical success rate among 10 patients studied.
- The study, conducted at Aichi Cancer Center Hospital, found that while there were some minor adverse events like fever, overall safety was high with no serious complications.
- With a median follow-up of 9.5 months, some patients achieved a stent-free state, suggesting EUS-PJS may reduce the need for further interventions and create a permanent drainage solution.
Oxaliplatin Added to Fluoropyrimidine/Bevacizumab as Initial Therapy for Unresectable Metastatic Colorectal Cancer in Older Patients: A Multicenter, Randomized, Open-Label Phase III Trial (JCOG1018).
J Clin Oncol
November 2024
Department of Clinical Oncology, Kochi Health Sciences Center, Kochi, Japan.
Purpose: Doublet chemotherapy with fluoropyrimidine (FP) and oxaliplatin (OX) plus bevacizumab (BEV) is a standard regimen for unresectable metastatic colorectal cancer (MCRC). However, the efficacy of adding OX to FP plus BEV (FP + BEV) remains unclear for older patients, a population for whom FP + BEV is standard. We aimed to confirm the superiority of adding OX to FP + BEV for this population.
View Article and Find Full Text PDFCorrection to: Treatment Decision for Locally Resected T1 Colorectal Carcinoma-Verification of the Japanese Guideline Criteria for Additional Surgery Based on Long-Term Clinical Outcomes.
Am J Gastroenterol
November 2024
Department of Surgery, National Defense Medical College, Tokorozawa, Japan.
A phase 3 study (PATHWAY) of palbociclib plus tamoxifen in patients with HR-positive/HER2-negative advanced breast cancer.
NPJ Breast Cancer
August 2024
Department of Medical Oncology, National Cancer Center Hospital, Tokyo, Japan.
Article Synopsis
- Palbociclib combined with tamoxifen was tested in a phase 3 study involving 184 women with HR+/HER2- advanced breast cancer to evaluate its efficacy and safety compared to tamoxifen alone.
- The results showed a significant improvement in progression-free survival (PFS), with a median of 24.4 months for the palbociclib-tamoxifen group versus 11.1 months for the placebo-tamoxifen group.
- While overall survival (OS) data is still being gathered, there is a trend suggesting palbociclib-tamoxifen may also reduce mortality risk, though neutropenia was a common severe side effect.